Intrinsic resistance to ROS1 inhibition in a patient with CD74‐ROS1 mediated by AXL overexpression

Abstract Background The vast majority of patients with ROS1 positive non‐small cell lung cancer (NSCLC) derive clinical benefit from currently approved ROS1 therapies, including crizotinib and entrectinib. However, a small proportion of patients treated with ROS1 inhibitors fail to derive any clinic...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Tara L. Peters, Nan Chen, Logan C. Tyler, Anh T. Le, Anastasios Dimou, Robert C. Doebele
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2023-11-01
Colecção:	Thoracic Cancer
Assuntos:	AXL drug resistance NSCLC ROS1
Acesso em linha:	https://doi.org/10.1111/1759-7714.15116
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!